Australian ChemGenex Anticipates March Approval For First Product Omapro For Gleevec-resistant CML Patients

PERTH, Australia - Melbourne-headquartered ChemGenex will see its first product Omapro under review by U.S. FDA's Oncologic Drugs Advisory Committee Feb. 10 for patients with chronic myeloid leukemia who have failed to respond to Gleevec and who have the Bcr-Abl T315I mutation